A biotechnology company focused on the development and commercialization of innovative therapeutic products for patients with chronic and life-threatening cardiovascular, cancer and infectious diseases.


Updates from The Motley Fool

Latest updates on United Therapeutics from Fool.com.  The Fool has written over 100 articles on United Therapeutics.
This Week in Biotech

With the  SPDR S&P Biotech Index  up 48% over the trailing-12-month period, it's evident that inv...

This Week in Biotech

With the  SPDR S&P Biotech Index  up 25% over the trailing-12-month period, it's evident that inv...



Stock Performance

View Interactive UTHR Charts
Sponsored by

Key Data Points

Primary metrics and data points about United Therapeutics.
Current Price: $129.37
Prev Close: $129.37
Open: $127.28
Bid: $126.75
Ask: $135.00
Day's Range: $127.28 - $131.13
52wk Range: $97.52 - $164.04
Volume: 506,009
Avg Vol 594,067
Market Cap: $6B
P/E (ttm): 8.49
EPS (ttm): $14.90
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about United Therapeutics.
CAPS Rating 4 out of 5
 
267 Outperform
17 Underperform
CAPS All Stars
 
78 Outperform
5 Underperform

How do you think United Therapeutics will perform against the market?



You pick for United Therapeutics is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Martine A. Rothblatt, CEO

92% Approve

Based on 35 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for United Therapeutics.

A biotechnology company focused on the development and commercialization of innovative therapeutic products for patients with chronic and life-threatening cardiovascular, cancer and infectious diseases.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers